On our latest episode of Prognosis, reporter Kristen V. Brown sells her DNA data to the highest bidder. Health data has turned into big business, but Brown quickly realized she wasn’t about to get rich. In exchange for an Amazon gift card or a few shares of marginal value, companies promise to use your data in the quest for better healthcare. 

See omnystudio.com/listener for privacy information.

On this episode of Prognosis, reporter Michelle Fay Cortez probes one of the more disturbing unintended consequences of the genetic testing revolution. DNA tests have become so prevalent that more and more people are discovering they have rare and potentially dangerous or even lethal genetic mutations. But how accurate are those findings? And what should people and their doctors do about them? Michelle tells the story of one family faced with the decision whether to proceed with life-altering surgeries to avoid facing a cancer diagnoses one day in the future.

See omnystudio.com/listener for privacy information.

A century-old quest for family records to unite relatives in heaven has transformed the church into a global leader in genealogy technology. That's paved the way for the success of companies like 23andMe who sell the promise of helping us figure out who are and where we come from.

See omnystudio.com/listener for privacy information.

On this new show from Bloomberg, hosts Mike Regan and Sarah Ponczek speak with expert guests each week about the main themes influencing global markets. They explore everything from stocks to bonds to currencies and commodities, and how each asset class affects trading in the others. Whether you’re a financial professional or just a curious retirement saver, What Goes Up keeps you apprised of the latest buzz on Wall Street and what the wildest movements in markets will mean for your investments. 

See omnystudio.com/listener for privacy information.

On this episode of Prognosis, we'll meet the Bloody Health collective – a group of feminist coders in Berlin who are looking for a safer way to track their periods. Targeted advertising, third-party data sharing and tracking make most menstruation apps just as problematic as they are popular, privacy activists argue. For the women of Bloody Health, the sure way to keep control is to build their own open-source app.

See omnystudio.com/listener for privacy information.

The Pay Check is back for a second season! For the next six weeks, we’re going to dig into the number one reason women still make less money than men: Motherhood. Women start their careers earning just about the same as men do, but once they have their first kid, that pay gap grows to a chasm. This season, we’ll show you how this “motherhood penalty” plays out for real women, in real life and how it affects the global economy.

See omnystudio.com/listener for privacy information.

On the latest edition of Prognosis, we'll tell you how a simple DNA genealogy test upended the life of a Washington state sheep farmer. Instead of finding out more about the Swedish and Jewish roots she'd heard about, she found that she had an entire family she didn't know about, and a connection to a man with a mysterious and controversial past. These types of genetic surprises are getting more common, and redefining who we call family.

See omnystudio.com/listener for privacy information.

Prognosis is back for a second season. Over the next few weeks, we're acknowledging how science and technology are making it easier for us to know pretty much everything there is to know about ourselves: Where we come from. The best time to conceive. What might kill us. And what happens when we start getting all that information, and handing it over to others.

See omnystudio.com/listener for privacy information.

The Pay Check is collecting stories for our upcoming season, and we want to hear from you! Did having a kid change your career trajectory or the way you work? If you have anything you want to share, call and leave us a voicemail at (212) 617-0166. Stay tuned for more very soon!

See omnystudio.com/listener for privacy information.

Some patients can't wait for pharmaceutical companies to develop drugs. They're pushing the drug industry to make the cures they and their loved ones need. But what's good for patients is also good for pharma's profits, creating a web of murky incentives that makes the issue of high drug costs all the more difficult to parse. In episode 8, Bloomberg's Rebecca Spalding talks to these professional patients about their relationships to the big companies whose therapies they need.

See omnystudio.com/listener for privacy information.